After determining the key effects of the CCL/CCR2 axis in macrophage accumulation and M1 polarization in the lung tissue, novel targeted delivery drug FNA-siCCR2 was synthesized to impede pulmonary fibrosis via selectively depleting M1 macrophages, thus shedding a light on the novel therapeutic strategy for IPF. The gene discussed is CCR2; the disease is idiopathic pulmonary fibrosis.